EVE Health Group Limited (EVE) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.242x

Based on the latest financial reports, EVE Health Group Limited (EVE) has a cash flow conversion efficiency ratio of -0.242x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-907.94K ≈ $-642.42K USD) by net assets (AU$3.76 Million ≈ $2.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of EVE Health Group Limited to measure how many days the company can operate on defensive assets alone.

EVE Health Group Limited - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how EVE Health Group Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

EVE Health Group Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EVE Health Group Limited ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
UPHEALTH INC
F:5XV
N/A
Goodbye Kansas Group AB (publ)
ST:GBK
0.025x
FENIXORO GOLD CORP.
F:8FD
N/A
Trainers House Oyj
HE:TRH1V
0.039x
Global Interactive Technologies, Inc
NASDAQ:GITS
-0.032x
Olenox Industries Inc.
NASDAQ:OLOX
-0.026x
Bank Danamon Indonesia Tbk
JK:BDMN
0.196x
LEHNER INVESTMENTS AG
F:LEH
N/A

Annual Cash Flow Conversion Efficiency for EVE Health Group Limited (2004–2025)

The table below shows the annual cash flow conversion efficiency of EVE Health Group Limited from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see EVE stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$3.55 Million
≈ $2.51 Million
AU$-1.62 Million
≈ $-1.14 Million
-0.455x +49.72%
2024-06-30 AU$1.22 Million
≈ $866.05K
AU$-1.11 Million
≈ $-783.25K
-0.904x -71.38%
2023-06-30 AU$3.12 Million
≈ $2.21 Million
AU$-1.65 Million
≈ $-1.17 Million
-0.528x +3.00%
2022-06-30 AU$6.93 Million
≈ $4.91 Million
AU$-3.77 Million
≈ $-2.67 Million
-0.544x -146.98%
2021-06-30 AU$10.19 Million
≈ $7.21 Million
AU$-2.24 Million
≈ $-1.59 Million
-0.220x +9.31%
2020-06-30 AU$12.99 Million
≈ $9.19 Million
AU$-3.16 Million
≈ $-2.23 Million
-0.243x -32.63%
2019-06-30 AU$5.85 Million
≈ $4.14 Million
AU$-1.07 Million
≈ $-757.90K
-0.183x -67.12%
2018-06-30 AU$7.38 Million
≈ $5.22 Million
AU$-808.76K
≈ $-572.25K
-0.110x +45.55%
2017-06-30 AU$2.78 Million
≈ $1.97 Million
AU$-558.99K
≈ $-395.52K
-0.201x +45.42%
2016-06-30 AU$1.75 Million
≈ $1.24 Million
AU$-645.76K
≈ $-456.92K
-0.369x -305.44%
2015-06-30 AU$2.64 Million
≈ $1.87 Million
AU$-240.46K
≈ $-170.14K
-0.091x -368.93%
2014-06-30 AU$8.11 Million
≈ $5.74 Million
AU$-157.19K
≈ $-111.23K
-0.019x +79.66%
2013-06-30 AU$8.18 Million
≈ $5.79 Million
AU$-779.82K
≈ $-551.77K
-0.095x -39.15%
2012-06-30 AU$23.04 Million
≈ $16.30 Million
AU$-1.58 Million
≈ $-1.12 Million
-0.069x +64.89%
2011-06-30 AU$25.64 Million
≈ $18.14 Million
AU$-5.00 Million
≈ $-3.54 Million
-0.195x -117.47%
2010-06-30 AU$25.15 Million
≈ $17.79 Million
AU$-2.26 Million
≈ $-1.60 Million
-0.090x +29.17%
2009-06-30 AU$22.93 Million
≈ $16.23 Million
AU$-2.91 Million
≈ $-2.06 Million
-0.127x -29.01%
2008-06-30 AU$25.64 Million
≈ $18.14 Million
AU$-2.52 Million
≈ $-1.78 Million
-0.098x -34.67%
2007-06-30 AU$18.78 Million
≈ $13.29 Million
AU$-1.37 Million
≈ $-969.08K
-0.073x -104.92%
2006-06-30 AU$5.98 Million
≈ $4.23 Million
AU$-212.78K
≈ $-150.56K
-0.036x +46.18%
2005-06-30 AU$2.22 Million
≈ $1.57 Million
AU$-146.87K
≈ $-103.92K
-0.066x +70.17%
2004-06-30 AU$251.35K
≈ $177.84K
AU$-55.71K
≈ $-39.42K
-0.222x --

About EVE Health Group Limited

AU:EVE Australia Packaged Foods
Market Cap
$5.44 Million
AU$7.69 Million AUD
Market Cap Rank
#28387 Global
#1513 in Australia
Share Price
AU$0.02
Change (1 day)
+4.76%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.04
About

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more